

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

6th February 2023**wheezo® REMOTE PATIENT MONITORING (RPM) SUCCESSFULLY REIMBURSED AND CLAIMED BY PHYSICIANS.****Highlights:**

- Respiri becomes the first Australian eHealth SaaS Company whose wheezo® medical device used for Remote Patient Monitoring by physicians in USA is now reimbursed by Centers of Medicare and Medicaid (CMS) in the USA.
- Respiri receiving recurring revenues per patient per month funded from these reimbursement claims and from wheezo® device sales.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce a key milestone in the execution of the Company USA business strategy.

Respiri has become the first Australian medical device manufacturer to have its patented wheezo® device, used for Remote Patient Monitoring (RPM) programs prescribed by physicians, to be successfully processed and receiving reimbursement from Centers of Medicare and Medicaid Services (CMS) in the USA. The RPM program, delivered by partner Access Telehealth, includes patient engagement and remote monitoring using the Access cloud-based platform, Remotli. Although not financially material, this event marks a key milestone in the execution of the Company’s USA business strategy.

CMS (and private insurers) provides RPM reimbursement to physicians based upon the eligibility of insured patients across all 50 US states. RPM Current Procedural Terminology (CPT) reimbursement codes covered the RPM solutions delivered through the Access Telehealth full-service premium model that includes patient engagement using their cloud-based platform, Remotli, including RPM CPT codes 99453, 99454 and 99457, totaling approximately USD124 per patient, per month to the claiming physicians.

Respiri generates monthly recurring revenues per patient when the wheezo® RPM program is successfully delivered and reimbursed by CMS, in addition to device sales. The wheezo® medical device is currently being used by 20 patients across a number of medical institutions/healthcare organisations who have engaged with Respiri’s partner, Access Telehealth, to use the wheezo® RPM program for patients who suffer from Respiratory Disorders, including asthma and Chronic Obstructive Pulmonary Disease (COPD). These numbers are expected to continue to grow as the wheezo® RPM program gains traction in the USA with a further 500 patients identified for onboarding in the short term. Respiri earns US\$50-60 for each device sale to RPM partner organisations and generates recurring revenues of US\$10-20 per month from the ongoing RPM use of the device with revenue dependent upon the scope of future services outsourced to RPM partners.

CMS provides universal reimbursement coverage for eligible patients across all 50 US states. Medicare provides insurance coverage for older Americans who are considered targets for RPM services. Most US private health insurers also reimburse RPM services. RPM is also mandated in 28 of the 50 US states making RPM reimbursement mandatory in those states.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

Reimbursement funded RPM monthly recurring patient revenue is a key element of the Respiri USA business model, making these claims a key milestone deliverable for the Company.

Marjan Mikel, CEO of Respiri said, “Receiving first reimbursement revenues for wheezo® RPM in the US is a major commercialization milestone for the company. The recurring patient revenue underpins our business model. This is generated by our ongoing engagement with physicians who prescribe the program and submit these claims to generate the wheezo® RPM reimbursement payments. We are also proud to be the first Australian eHealth Company whose device has been prescribed by physicians for RPM and successfully reimbursed. We continue to focus our efforts on scaling up operations to engage with and gain acceptance of the wheezo® RPM product from both existing and new medical institutions by offering a new standard of care in the US medical industry.”

Given the significant business progress that Respiri has made over the past year resulting in engagement of five medical institutions/healthcare organisations since November 2022, the Company is focused on ensuring that it is ready to meet the anticipated demand generated by increased patient enrolment from existing and new healthcare organisation customers and continue to improve the physician, customer and patient wheezo® RPM experience.

This announcement has been approved by the Board of Respiri Limited

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director

Respiri Limited

P: +61 408 462 873

E: marjan@respiri.co

Mr Nicholas Smedley

Executive Chairman

Respiri Limited

P: +61 447 074 160

E: nicholas@respiri.co

wheezo® is a registered trademark of Respiri Limited.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website www.respiri.co/au

About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit www.respiri.co/us

wheezo® is a registered trademark of Respiri Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com/

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.